CapWealth Advisors LLC lifted its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 9.4% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 205,190 shares of the biopharmaceutical company’s stock after purchasing an additional 17,592 shares during the quarter. Bristol-Myers Squibb comprises about 1.9% of CapWealth Advisors LLC’s portfolio, making the stock its 20th largest holding. CapWealth Advisors LLC’s holdings in Bristol-Myers Squibb were worth $10,666,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently made changes to their positions in BMY. Oregon Public Employees Retirement Fund raised its position in Bristol-Myers Squibb by 2,326.3% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 9,230,504 shares of the biopharmaceutical company’s stock worth $178,000 after buying an additional 8,850,072 shares during the last quarter. MERIAN GLOBAL INVESTORS UK Ltd raised its position in Bristol-Myers Squibb by 6,090.3% during the 4th quarter. MERIAN GLOBAL INVESTORS UK Ltd now owns 4,130,436 shares of the biopharmaceutical company’s stock worth $214,700,000 after buying an additional 4,063,712 shares during the last quarter. Prudential Financial Inc. raised its position in Bristol-Myers Squibb by 90.9% during the 4th quarter. Prudential Financial Inc. now owns 4,967,474 shares of the biopharmaceutical company’s stock worth $257,891,000 after buying an additional 2,365,961 shares during the last quarter. Two Sigma Advisers LP raised its position in Bristol-Myers Squibb by 96.1% during the 4th quarter. Two Sigma Advisers LP now owns 2,783,732 shares of the biopharmaceutical company’s stock worth $144,698,000 after buying an additional 1,363,900 shares during the last quarter. Finally, Vanguard Group Inc raised its position in Bristol-Myers Squibb by 1.0% during the 3rd quarter. Vanguard Group Inc now owns 128,376,159 shares of the biopharmaceutical company’s stock worth $7,969,593,000 after buying an additional 1,229,553 shares during the last quarter. 74.27% of the stock is owned by hedge funds and other institutional investors.

NYSE:BMY opened at $45.98 on Wednesday. The company has a quick ratio of 1.50, a current ratio of 1.61 and a debt-to-equity ratio of 0.40. The company has a market cap of $75.83 billion, a PE ratio of 11.55, a PEG ratio of 2.38 and a beta of 0.80. Bristol-Myers Squibb Co has a 1-year low of $44.30 and a 1-year high of $63.69.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, January 24th. The biopharmaceutical company reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.09. The firm had revenue of $5.97 billion during the quarter, compared to analyst estimates of $5.95 billion. Bristol-Myers Squibb had a net margin of 21.95% and a return on equity of 48.99%. The business’s quarterly revenue was up 9.6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.68 EPS. Analysts expect that Bristol-Myers Squibb Co will post 4.15 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be issued a dividend of $0.41 per share. This represents a $1.64 annualized dividend and a dividend yield of 3.57%. The ex-dividend date of this dividend is Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 41.21%.

A number of equities analysts have issued reports on BMY shares. Morgan Stanley set a $54.00 price target on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Thursday, December 20th. BMO Capital Markets reissued a “buy” rating and set a $59.00 price target on shares of Bristol-Myers Squibb in a research report on Tuesday, February 19th. Credit Suisse Group reissued a “hold” rating and set a $59.00 price target on shares of Bristol-Myers Squibb in a research report on Thursday, December 13th. Societe Generale raised shares of Bristol-Myers Squibb from a “sell” rating to a “buy” rating in a research report on Tuesday, January 15th. Finally, Edward Jones lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Friday, January 4th. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating and six have assigned a buy rating to the company. Bristol-Myers Squibb presently has an average rating of “Hold” and an average target price of $59.13.

TRADEMARK VIOLATION WARNING: “Bristol-Myers Squibb Co (BMY) Shares Bought by CapWealth Advisors LLC” was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this article on another site, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this article can be viewed at https://www.watchlistnews.com/bristol-myers-squibb-co-bmy-shares-bought-by-capwealth-advisors-llc/2952278.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Featured Story: Why is cost of goods sold important?

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.